- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02303795
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 04004050
- Associação do Sanatório Sírio - Hospital do Coração HCor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged >18 years at time of inclusion
Patients with Persistent or paroxysmal Atrial Fibrillation or flutter with bioprosthetic mitral valves.
- The patient must be able to give informed consent
Exclusion Criteria:
Cardiovascular-related conditions as known presence of cardiac thrombus or tumor
- Active endocarditis
- Uncontrolled hypertension
Hemorrhage risk-related criteria
- Active internal bleeding
- History of, or condition associated with, increased bleeding risk
Concomitant conditions and therapies
History of previous thromboembolism with high risk of bleeding:
- Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months
- Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization
- Acute MI within the last 14 days prior to randomization
- Treatment with: Chronic aspirin therapy > 100 mg daily or dual antiplatelet therapy; Intravenous antiplatelets; Fibrinolytics; Anticipated need for long-term treatment with a nonsteroidal antiinflammatory drug; Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as ketoconazole or protease inhibitors; Treatment with a strong inducer of cytochrome P450 3A4, such as rifampicin, phenytoin, phenobarbital, or carbamazepine.
- Anemia
- Pregnancy or breastfeeding or women of reproductive age not using effective contraceptive methods
- Calculated creatinine clearance bellow 30 mL/min
- Known significant liver disease or alanine aminotransferase N3× the upper limit of normal
- Previous participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Rivaroxaban 20mg
Oral Rivaroxaban, 20 mg od.
Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
|
Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od.
Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0. Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day. |
Active Comparator: Warfarin
Warfarin Warfarin once daily (q.d.).
The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
|
Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od.
Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0. Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Clinical Events
Time Frame: 12 months
|
Combined Endpoint of major clinical events as defined by strokes (CVA), transient ischemic attack (TIA), major bleeding, all-cause death, valve thrombosis and non-CNS systemic embolism, hospitalization due to cardiac failure.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major bleeding
Time Frame: 12 months
|
Clinically overt bleeding associated with: fatal outcome, involving a critical site, or clinically overt bleeding associated with a fall in hemoglobin concentration of ≥2 g/dL, or leading to transfusion of ≥2 units of packed red blood cells or whole blood.
|
12 months
|
Combined endpoint of nonfatal stroke (CVA), transient ischemic attack (TIA), systemic embolism, valve thrombosis, venous thromboembolism and vascular causes death.thrombosis, and vascular death
Time Frame: 12 months
|
Stroke: sudden, focal neurologic deficit from a presumed cerebrovascular cause, not reversible within 24 hours and not due to na identifiable cause. Non-CNS systemic embolism: abrupt vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion. Valve thrombosis: any thrombus attached to or near an implanted valve that occludes part of the blood flow, interferes with function or warrant treatment. Mortality: Deaths any cause. Venous thromboembolism: verification by definitive diagnostic evaluation. Deep Vein Thrombosis: abnormal compression ultrasound or intraluminal filling defect on venography or autopsy. Pulmonary embolism: at least one: 1) intraluminal filling defect on CT scan; 2) intraluminal filling defect on pulmonary angiogram; 3) high- probability on v/p lung scan; 4)inconclusive spiral CT, pulmonary image with demonstration of DVT in the lower extremities; 5) autopsy |
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ricardo Pavanello, MD, PhD, Hospital do Coracao
- Principal Investigator: Helio P Guimarães, MD, PhD, Hospital do Coracao
Publications and helpful links
General Publications
- Guimaraes HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, Hoffmann-Filho CR, de Lemos Soares Patriota R, Leiria TLL, Lamprea D, Precoma DB, Atik FA, Silveira FS, Farias FR, Barreto DO, Almeida AP, Zilli AC, de Souza Neto JD, Cavalcante MA, Figueira FAMS, Kojima FCS, Damiani L, Santos RHN, Valeis N, Campos VB, Saraiva JFK, Fonseca FH, Pinto IM, Magalhaes CC, Ferreira JFM, Alexander JH, Pavanello R, Cavalcanti AB, Berwanger O; RIVER Trial Investigators. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
- Guimaraes HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, Paixao M, Hoffmann-Filho CR, Patriota R, Leiria TLL, Lamprea D, Precoma DB, Atik FA, Silveira FS, Farias FR, Barreto DO, Almeida AP, Zilli AC, de Souza Neto JD, Cavalcante MA, Figueira FAMS, Junior RA, Moises VA, Mesas CE, Ardito RV, Kalil PSA, Paiva MSMO, Maldonado JGA, de Lima CEB, D'Oliveira Vieira R, Laranjeira L, Kojima F, Damiani L, Nakagawa RH, Dos Santos JRY, Sampaio BS, Campos VB, Saraiva JFK, Fonseca FH, Pinto IM, Magalhaes CC, Ferreira JFM, Lopes RD, Pavanello R, Cavalcanti AB, Berwanger O; RIVER (RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial) Investigators. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. Am Heart J. 2021 Jan;231:128-136. doi: 10.1016/j.ahj.2020.10.001. Epub 2020 Oct 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Heart Diseases
- Atrial Fibrillation
- Heart Valve Diseases
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Warfarin
Other Study ID Numbers
- RIVER01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Valvular Heart Disease
-
Dacima ConsultingTunisian Society of Cardiology and Cardiovascular SurgeryCompletedValvular Heart Disease | Valvular Stenosis | Valvular InsufficiencyTunisia
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
University of PennsylvaniaCompleted
-
Assiut UniversityCompleted
-
Cliniques universitaires Saint-Luc- Université...RecruitingValvular Heart Disease Stenosis and Regurgitation (Diagnosis)Belgium
-
Assiut UniversityActive, not recruitingValvular Heart Disease Stenosis and RegurgitationEgypt
-
Assiut UniversityRecruitingValvular Heart Disease Stenosis and RegurgitationEgypt
-
Ruijin HospitalMed-X Research Institute, Shanghai Jiao Tong UniversityRecruitingPrimary Valvular Heart Disease With Comorbid Coronary Artery Disease | Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart DiseaseChina
-
Cardenal Herrera UniversityUniversity of Valencia; Hospital de la RiberaNot yet recruitingExercise Based Prehabilitation in Valvular SurgerySpain
-
Yonsei UniversityCompletedValvular Heart Disease PatientsKorea, Republic of
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of